Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
View/ Open
Date
2017-04-01Author
Papadatos-Pastos, D
Roda, D
De Miguel Luken, MJ
Petruckevitch, A
Jalil, A
Capelan, M
Michalarea, V
Lima, J
Diamantis, N
Bhosle, J
Molife, LR
Banerji, U
de Bono, JS
Popat, S
O'Brien, MER
Yap, TA
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection for phase I trials based on albumin, number of disease sites and LDH. Patients with mesothelioma are often selected for phase I trials as the disease remains localised for long periods of time. We have now reviewed the clinical outcomes of patients with relapsed malignant mesothelioma (MM) and propose a specific mesothelioma prognostic score (m-RPS) that can help identify patients who are most likely to benefit from early referral. METHODS: Patients who participated in 38 phase I trials between September 2003 and November 2015 were included in the analysis. Efficacy was assessed by response rate, median overall survival (OS) and progression-free survival (PFS). Univariate (UVA) and multivariate analyses (MVA) were carried out to develop the m-RPS. RESULTS: A total of 65 patients with advanced MM were included in this retrospective study. The PFS was 2.5 months (95% confidence interval [CI] 2.0-3.1 months) and OS was 8 months (95% CI 5.6-9.8 months). A total of four (6%) patients had RECIST partial responses, whereas 26 (40%) patients had RECIST stable disease >3 months. The m-RPS was developed comprising of three different prognostic factors: a neutrophil: lymphocyte ratio greater than 3, the presence of more than two disease sites (including lymph nodes as a single site of disease) and albumin levels less than 35 from the MVA. Patients each received a score of 1 for the presence of each factor. Patients in group A (m-RPS 0-1; n = 35) had a median OS of 13.4 months (95% CI 8.5-21.6), whereas those in group B (m-RPS 2-3; n = 30) had a median OS of 4.0 months (95% CI 2.9-7.1, P < 0.0001). A total of 56 (86%) patients experienced G1-2 toxicities, whereas reversible G3-4 toxicities were observed in 18 (28%) patients. Only 10 (15%) patients discontinued phase I trials due to toxicity. CONCLUSIONS: Phase I clinical trial therapies were well tolerated with early signals of antitumour activity in advanced MM patients. The m-RPS is a useful tool to assess MM patient suitability for phase I trials and should now be prospectively validated.
Collections
Subject
Humans
Mesothelioma
Peritoneal Neoplasms
Pleural Neoplasms
Disease Progression
Antineoplastic Combined Chemotherapy Protocols
Protein Kinase Inhibitors
Disease-Free Survival
Treatment Outcome
Retrospective Studies
Adult
Aged
Middle Aged
Female
Male
Clinical Trials, Phase I as Topic
Molecular Targeted Therapy
Phosphoinositide-3 Kinase Inhibitors
Research team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Prostate Cancer Targeted Therapy Group
Thoracic Oncology
Treatment of thoracic tumours
Language
eng
Date accepted
2016-12-22
License start date
2017-04
Citation
European journal of cancer (Oxford, England : 1990), 2017, 75 pp. 56 - 62
Publisher
ELSEVIER SCI LTD